Clinical Efficacy of Fuzheng Guben Anticancer Decoction Combined with Taxol in Treating Ovarian Carcinoma and Its Effect on Complication Incidence

Table 1

General information (n = 40).

Observation indicator	Control	Experimental	X^2/t
Age (years)	51.17 ± 8.58	51.30 ± 8.79	0.067	0.947
BMI (kg/m^2)	23.24 ± 2.11	23.15 ± 2.08	0.192	0.848
Course of the disease (years)	2.27 ± 0.30	2.31 ± 0.32	0.577	0.566
TNM stage
IIIa	18 (45%)	21 (52.5%)	0.450	0.502
IIIb	14 (35%)	13 (32.5%)	0.056	0.813
IV	8 (20%)	6 (15%)	0.346	0.556
Pathological type
Serous cystadenocarcinoma	12 (30%)	13 (32.5%)	0.058	0.809
Mucinous cystadenocarcinoma	10 (25%)	8 (20%)	0.287	0.592
Granular cell carcinoma	7 (17.5%)	8 (20%)	0.082	0.775
Embryonal carcinoma	7 (17.5%)	6 (15%)	0.092	0.762
Undifferentiated carcinoma	4 (10%)	5 (12.5%)	0.125	0.723